<div id="readability-page-1"><div><div><p>Throughout the last three months, 7 analysts have evaluated Procter &amp; Gamble <span>PG</span>, offering a diverse set of opinions from bullish to bearish.</p><p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p><figure><table><thead><tr><th></th><th><strong>Bullish</strong></th><th><strong>Somewhat Bullish</strong></th><th><strong>Indifferent</strong></th><th><strong>Somewhat Bearish</strong></th><th><strong>Bearish</strong></th></tr></thead><tbody><tr><td><strong>Total Ratings</strong></td><td>4</td><td>3</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>Last 30D</strong></td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>1M Ago</strong></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>2M Ago</strong></td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><strong>3M Ago</strong></td><td>3</td><td>2</td><td>0</td><td>0</td><td>0</td></tr></tbody></table></figure><p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $176.43, a high estimate of $187.00, and a low estimate of $168.00. Surpassing the previous average price target of $171.67, the current average has increased by 2.77%.</p><p><span><span></span><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1719234044_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="3840" height="2742" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2024/1719234044_0.png/query-YXV0bz13ZWJwJmRwcj0yJm9wdGltaXplPW1lZGl1bSZ3aWR0aD0xOTIw"/></span></p><h2>Interpreting Analyst Ratings: A Closer Look</h2><p>The standing of Procter &amp; Gamble among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><figure><table><thead><tr><th>Analyst</th><th>Analyst Firm</th><th>Action Taken</th><th>Rating</th><th>Current Price Target</th><th>Prior Price Target</th></tr></thead><tbody><tr><td>Kevin Grundy</td><td>Exane BNP Paribas</td><td>Announces</td><td>Outperform</td><td>$187.00</td><td>-</td></tr><tr><td>Chris Graja</td><td>Argus Research</td><td>Raises</td><td>Buy</td><td>$185.00</td><td>$180.00</td></tr><tr><td>Lauren Lieberman</td><td>Barclays</td><td>Raises</td><td>Overweight</td><td>$170.00</td><td>$168.00</td></tr><tr><td>Steve Powers</td><td>Deutsche Bank</td><td>Lowers</td><td>Buy</td><td>$171.00</td><td>$172.00</td></tr><tr><td>Kaumil Gajrawala</td><td>Jefferies</td><td>Raises</td><td>Buy</td><td>$182.00</td><td>$175.00</td></tr><tr><td>Lauren Lieberman</td><td>Barclays</td><td>Raises</td><td>Overweight</td><td>$168.00</td><td>$165.00</td></tr><tr><td>Steve Powers</td><td>Deutsche Bank</td><td>Raises</td><td>Buy</td><td>$172.00</td><td>$170.00</td></tr></tbody></table></figure><h3>Key Insights:</h3><ul><li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Procter &amp; Gamble. This information provides a snapshot of how analysts perceive the current state of the company.</li><li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li><li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Procter &amp; Gamble's stock. This comparison reveals trends in analysts' expectations over time.</li></ul><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Procter &amp; Gamble's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p><p><strong>Stay up to date on Procter &amp; Gamble analyst ratings.</strong></p><h2>Discovering Procter &amp; Gamble: A Closer Look</h2><p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. P&amp;G sold its last remaining food brand, Pringles, to Kellogg in calendar 2012. Sales outside its home turf represent around 53% of the firm's consolidated total.</p><h3>Procter &amp; Gamble: A Financial Overview</h3><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p><p><strong>Revenue Growth:</strong> Over the 3 months period, Procter &amp; Gamble showcased positive performance, achieving a revenue growth rate of <strong>0.63%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Staples sector.</p><p><strong>Net Margin:</strong> Procter &amp; Gamble's net margin excels beyond industry benchmarks, reaching <strong>18.25%</strong>. This signifies efficient cost management and strong financial health.</p><p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>7.6%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.07%,</strong> the company showcases effective utilization of assets.</p><p><strong>Debt Management:</strong> Procter &amp; Gamble's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.65</strong>.</p><h2>Analyst Ratings: What Are They?</h2><p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically rate each stock once per quarter.</p><p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p></div></div></div>

<p>Procter & Gamble (PG) has been evaluated by 7 analysts over the past three months, with a range of opinions from bullish to bearish. The average 12-month price target is $176.43, indicating a 2.77% increase from the previous target. Analyst actions reflect their response to market conditions and company performance, with ratings ranging from 'Outperform' to 'Underperform'. Procter & Gamble's financial overview shows a strong market position and revenue growth, but potential challenges in generating satisfactory returns for shareholders. The company has a low debt-to-equity ratio and effective utilization of assets.</p>

A Glimpse Into The Expert Outlook On Procter & Gamble Through 7 Analysts